Reducing human suffering by detecting cancer earlier with patented technology
BioCurex's RECAF(tm) marker is found in all types of major cancers
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit Portfolio

Email Updates

Search

AGORACOM News Flash

AGORACOM WIRE - MONDAY MAY 28TH, 2012

SONOMAX completes $3 million equity financing

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc. Read More   |   *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013  Read More   |   *SPONSOR

 

 

Message: Great article...thank you

080115_sheen
Rank: [?]
Treasurer
Points: [?]
835
Rating: [?]
Votes: 11 Score: 2.7
  • Currently 2.7/5 Stars.
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Great article...thank you

posted on Mar 19, 09 08:55AM

Great read...thank you for keeping investors informed.



"Screening is not only an issue in prostate cancer. If the European study is correct, mammography has about the same benefit as the PSA test, said Dr. Michael B. Barry, a prostate cancer researcher at Massachusetts General Hospital who wrote an editorial accompanying the papers. But prostate cancers often are less dangerous than breast cancers, so screening and subsequent therapy can result in more harm. With mammography, about 10 women receive a diagnosis and needless treatment for breast cancer to prevent one death. With both cancers, researchers say they badly need a way to distinguish tumors that would be deadly without treatment from those that would not."

New Message

Please login to post a reply

AGORACOM Quick Tips

Small-Cap CEO Lessons - Is Your CEO Out Of Touch? ... Not Anymore

President's D.D.

New feature: Hub Presidents can add important links here.

Stock Quote